Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Five Prime Therapeutics (FPRX) aims to complete Phase 1a/1b study of FPA008 in combination with Nivolumab in patients with selected advanced cancers in 2018

Source Link:: https://clinicaltrials.gov/ct2/show/NCT02526017?term=five+prime+therapeutics&recr=Open&rank=1&submit_fld_opt=

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

FPRX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details BMS, a leader in immuno-oncology, is responsible for funding this study

http://www.fiveprime...

Additional Relevant Details Update on Aug 8 2018:

Enrollment has closed and treatment continues in Five Prime’s Phase 1a/1b clinical trial of cabiralizumab and OPDIVO (nivolumab).

http://investor.five...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 01, 2019

Occurred Source:

http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-presents-monotherapy-data-phase-1a1b

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Fpa 008, Nivolumab, Phase 1 Study, Non-small Cell Lung Cancer, Melanoma, Pancreatic Cancer, Colorectal Cancer, Glioblastoma, Head & Neck Cancer